Kaplan–Meier estimator
Kaplan–Meier estimator, also known as the Kaplan–Meier survival curve, is a non-parametric statistic used to estimate the survival function from lifetime data. In medical research, it is often used to measure the fraction of patients living for a certain amount of time after treatment. The Kaplan–Meier estimator is a way to estimate and plot the survival probabilities over time, despite having some censored data, which is common in clinical trials.
Overview[edit | edit source]
The Kaplan–Meier estimator is a product-limit estimator, which calculates the probability of survival at different times. It is used when the survival probabilities are not known at all time points. The estimator was introduced by Edward L. Kaplan and Paul Meier in 1958, who each submitted similar papers to the Journal of the American Statistical Association. The papers were combined and published together due to their similarity.
Calculation[edit | edit source]
The Kaplan–Meier survival curve is a step function that jumps at each event time. For a given time, the survival probability is calculated as follows:
S(t) = ∏ (1 - d_i / n_i)
where S(t) is the probability of survival until time t, d_i is the number of events (e.g., deaths) at time t_i, and n_i is the number of subjects at risk just before time t_i. The product is taken over all times t_i less than or equal to t.
Assumptions[edit | edit source]
The Kaplan–Meier estimator makes two key assumptions: 1. The survival probabilities are the same for subjects recruited early and late in the study. 2. Censoring is non-informative, meaning that the reason for censoring is unrelated to the likelihood of the event of interest.
Applications[edit | edit source]
The Kaplan–Meier estimator is widely used in clinical trials to estimate survival rates and compare the effectiveness of treatments. It is also used in other fields, such as engineering and sociology, to model time-to-event data.
Limitations[edit | edit source]
While the Kaplan–Meier estimator is a powerful tool, it has limitations. It cannot handle competing risks directly and does not account for covariates. For these situations, other methods like the Cox proportional hazards model may be more appropriate.
See also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD